As per stats released by the World Cancer Research Fund International, around 430,000 new cases of bladder cancer were diagnosed in 2012, with bladder cancer being the ninth-most common cancer. The bladder holds urine before it leaves the body during urination. The disease in which cancerous cells form in the tissues of the bladder is known as bladder cancer. There are three major types of bladder cancer and are named on the basis of type of cells become cancerous (malignant). These type are as follows –
According to the study of American Society of Clinical Oncology (ASCO), urothelial carcinoma accounts for around 90%, squamous cell carcinoma accounts 4% and adenocarcinoma accounts 2% of all bladder cancer. The remaining 4% bladder cancer includes other rare type of bladder cancer viz. sarcoma and small cell anaplastic cancer.
There are different types of treatment followed by doctors, which are mostly dependent on the patient’s preference for treatment and also based on type, possible side effects of the treatment and stage of bladder cancer.
Bladder cancer therapeutics market taxonomy:
Global Market by Bladder Cancer Type
Global Market by Treatment Type
Global Market by Test Type
Global Market by Gender
Global Market by Geography
Increasing incidence rate, especially in developed regions fueling growth of bladder cancer therapeutics market
As per stats released by the International Agency for Research on Cancer (IARC), 59% of bladder cancer cases are observed in developed countries, with Belgium reporting the highest number of bladder cancer cases.
As per stats released by Cancer Research UK—a charity involved in cancer research and development—here were around 10,100 new cases reported in the U.K. in 2014. Bladder cancer accounts for around 3% of all new cancer cases reported in the U.K. As per a study by the American Society of Clinical Oncology (ASCO), incidence rate of the disease has decreased by around 12% in the U.K. in the recent past.
According a study by Cancer Research Institute, bladder cancer is more prevalent among men than women. Around 77,000 new cases were diagnosed in the U.S. in 2016, leading to 16,000 deaths. Continuous advancements in clinical research resulted into increased survival rate of people suffering from bladder cancer, which is around 77% observed in last few years. As per the stats of American Cancer Society, bladder cancer accounts for 5% of all new cancer cases in the U.S.
Some are the major reasons behind bladder cancer are unhealthy habits. Smoking is a major cause along with that continuous exposure of industrial chemicals, drinking water with high level of arsenic, family history of bladder cancer, and long-term use of urinary catheters are the other causes of bladder cancer. In Africa and Middle East schistosomiasis and infested water are the leading cause of bladder cancer.
North America holds major share in the global bladder cancer therapeutics market, followed by Europe due to advanced treatments, developed economy, and easy access to advanced healthcare facilities. The market in APAC region will witness high growth rate in the near future, due to increasing per capita income, developing economy, government initiatives on improving healthcare infrastructure, growing FDI in healthcare, and rapidly increasing aging population. As per stats released by the Department of Industrial Policy and Promotion (DIPP), the healthcare sector in India witness FDI worth US$ 4.09 billion between April 2000 and September 2016. Also, medical tourism in the region is a flourishing business, due to easy access to high-quality low-cost treatment option. According to data released by the India Brand Equity Foundation (IBEF)— a Trust established by the Department of Commerce, Ministry of Commerce and Industry, Government of India—the medical tourism industry in India rakes in US$ 3 billion each year. This creates a highly conducive environment for growth of the bladder cancer therapeutics market in the region.
Conversely, increasing use of generic drugs, high cost of treatment, asymptomatic nature of the disease and fewer pipeline products inhibit growth of the market. As per data released by the American Cancer Society, only one drug received approval from FDA in last three decade.
The major companies playing key role in bladder therapeutics market are Sanofi S.A., F. Hoffmann-La Roche AG, Novartis, Pfizer, Eli Lilly and Co., GlaxoSmithKline, Bristol-Myers Squibb, Allergan Inc, AVI Biopharma Inc., and AstraZeneca plc. Some are the major drugs approved by Food and Drug Administration used for the treatment of bladder cancer are Cisplatin, Nivolumab, Thiotepa, Atezolizumab, Doxorubicin Hydrochloride, Opdivo (Nivolumab), Platinol-AQ (Cisplatin), Platinol (Cisplatin), and Tecentriq (Atezolizumab).
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized email@example.com
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.